Michael L. VAZQUEZ et al. U.S. Patent Application Serial No. 10/812,343

REMARKS

The first paragraph of the specification has been amended to update the priority claim by

inserting the patent number of the now-issued parent patent.

Claims 20-31 are pending in this application. Claims 1-19 were cancelled without

prejudice or disclaimer in the Preliminary Amendment filed March 30, 2004. New claim 32 is

directed to a class of compounds and their pharmaceutically acceptable salts, as described

throughout the originally-filed specification. For example, see page 36, lines 15-21 and

originally-filed claim 8.

Claims 20-26 have been amended to clarify that the claims embrace pharmaceutically

acceptable salts of the recited compounds. Support for these amendments is found throughout

the originally-filed specification. For example, see page 192, line 37 to page 193, line 30.

Accordingly, no new matter has been added.

Prompt and favorable examination on the merits of the pending claims is respectfully

solicited.

Datas

By:

Joseph M. Skerpon Registration No. 29,864

Respectfully submitted,

Banner & Witcoff, Ltd. 1001 G Street, NW

1001 G Street, NW

Washington, DC 20001

202-824-3000

Page 14 of 14